Gilead Sciences filings document material events, operating results, governance matters and capital-structure disclosures for a Delaware biopharmaceutical company whose common stock trades as GILD on the Nasdaq Global Select Market. Form 8-K reports furnish quarterly and annual financial results, including GAAP and non-GAAP measures and reconciliations, and disclose completed acquisition activity affecting oncology pipeline assets.
Proxy and annual meeting filings record director elections, auditor ratification and shareholder voting outcomes. Other current reports cover executive and governance changes, Regulation FD disclosures, material agreements, and formal exhibits tied to Gilead’s virology and oncology business, including clinical or regulatory disclosure categories when they are part of the company’s public reporting.
Gilead Sciences director Kelly A. Kramer received new equity awards as compensation. On April 30, 2026, Kramer was granted a non-qualified stock option covering 4,884 shares of Gilead common stock at an exercise price of $130.84 per share, expiring in 2036, with all shares vesting immediately on the grant date.
On the same date, Kramer also received 1,146 restricted stock units, each representing the right to receive one share of Gilead common stock. These RSUs vested 100% immediately at grant. Following the RSU award, Kramer’s reported RSU holdings totaled 20,256 units. These are awards from the company, not open‑market purchases.
Gilead Sciences, Inc. held its 2026 annual stockholder meeting, where a quorum was reached with 1,130,179,690 of 1,241,222,013 entitled shares represented. Stockholders elected nine directors for one-year terms and ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Stockholders approved, on an advisory basis, compensation for Named Executive Officers and also approved the amended and restated 2022 Equity Incentive Plan. Three stockholder proposals—calling for an independent Board Chair policy, a report on extended patent exclusivities and patient access, and a report on ESG and DEI compensation metrics—did not receive approval.
Gilead Sciences Inc reported a 13G filing showing 7.51% ownership represented by 93,327,127 shares. Vanguard Capital Management states it has sole dispositive power over 93,327,127 shares and sole voting power for 12,672,351 shares, and discloses affiliated investment divisions that exercise voting or dispositive authority.
Gilead Sciences Chairman & CEO Daniel O'Day sold 10,000 shares of common stock in open-market trades. The sales occurred on April 28, 2026 at prices around $128.79 and $130.01 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 28, 2025. Following the sales, he continues to hold more than 600,000 shares of Gilead common stock directly.
Daniel O'Day reported a Form 144 notice to sell securities related to GILD. The notice lists an intended sale of 10,000 performance shares with an offering date of 02/03/2026 through Morgan Stanley Smith Barney LLC. The form also discloses three sales completed earlier: 115,640 shares for $17,346,000 on 02/05/2026, 10,000 shares for $1,447,859 on 02/27/2026, and 10,000 shares for $1,368,162 on 03/27/2026.
Gilead Sciences has completed its acquisition of Arcellx, gaining full control of anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR T therapy for multiple myeloma. Gilead is paying $115 in cash per Arcellx share plus a non-transferable $5 contingent value right (CVR) per share.
The deal implies total equity value of about $7.8 billion and required roughly $7.1 billion of cash to close, including equity awards and related payments. About 38.8 million Arcellx shares, representing 77.2% of outstanding shares, were tendered before a follow-on merger made Arcellx a wholly owned Gilead subsidiary.
The CVR pays $5 in cash per share if cumulative global net sales of anito-cel reach $6.0 billion from launch through the end of 2029. Gilead expects to account for the transaction as an asset acquisition and estimates the deal will reduce 2026 diluted EPS by approximately $5.57 to $5.67, be modestly dilutive in 2026 and 2027 excluding acquired R&D, and become accretive in 2028 and later if anito-cel receives FDA approval.
Gilead Sciences’ Chief Financial Officer Andrew D. Dickinson reported an open-market sale of company stock. On this Form 4, he sold 3,000 shares of Gilead Sciences common stock at a price of $140.96 per share.
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2024, indicating it was scheduled in advance. Following this sale, Dickinson continues to hold 176,191 shares of Gilead Sciences common stock directly.
Gilead Sciences, Inc. executive Johanna Mercier, Chief Commercial & Corporate Affairs Officer, sold 3,000 shares of common stock at $140.96 per share in an open-market transaction. After this sale, she directly holds 128,779 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 20, 2025, indicating the timing was set in advance.
Johanna Mercier reported sales of restricted common stock. The filing lists two completed dispositions: 28,000 shares sold on 02/17/2026 for $4,324,227.70 and 3,000 shares sold on 03/16/2026 for $432,690.00. The form also lists restricted stock entries dated 12/10/2024 (1,519 shares) and 09/10/2024 (1,481 shares) as securities to be sold.
The transactions are reported on a Form 144-style disclosure and show sales by an individual filing. The filing records trade dates and gross proceeds for each completed sale; additional timing or proceeds treatment for the restricted shares listed to be sold is not provided in the excerpt.
Morgan Stanley Smith Barney LLC notice of proposed sale under Form 144 relating to 3,000 common shares described as Performance Shares dated 01/24/2023. The filing lists two prior sales by Andrew Dickinson: 3,000 shares on 03/16/2026 for $432,690 and 3,000 shares on 02/17/2026 for $463,290.